ArticleiGIE : innovation, investigation and insights2026
Thinking outside the box: leveraging endoscopic ultrasound-guided portal pressure gradient for comprehensive risk stratification in liver transplantation candidates.
Article in iGIE : innovation, investigation and insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Coronary artery disease (CAD) is common in liver transplantation (LT) candidates and may require coronary artery bypass grafting (CABG). Risk stratification is challenging in cirrhosis because histology alone does not reliably predict clinically significant portal hypertension (CSPH). Endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) provides minimally invasive, real-time hemodynamic assessment. The aim of this study was to evaluate the role of EUS-PPG in perioperative risk stratification among LT candidates requiring CABG. Methods: We retrospectively reviewed 3 LT candidates with hepatocellular carcinoma (HCC) as the indication for transplant (2021-2023). All had obstructive multivessel CAD not amenable to percutaneous coronary intervention and were evaluated for CABG using EUS-PPG when feasible. Results: Two patients with biopsy-proven cirrhosis had PPG <6 mm Hg, excluding CSPH; both underwent CABG and successful LT. In 1 patient, PPG could not be obtained because of anatomical distortion; CABG proceeded urgently, but the patient died postoperatively from stroke and aspiration pneumonia, which were unrelated to portal hypertension. Conclusions: EUS-PPG may be safe and clinically informative, complementing the Model for End-Stage Liver Disease-based risk stratification and histology to refine perioperative risk assessment in LT candidates with HCC and CAD, although additional cases and further study are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.